Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial

Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo on behalf of the TOCIVID-19 investigators (see Appendix for a complete list), Italy
doi: https://doi.org/10.1101/2020.06.01.20119149

Article Information

doi 
https://doi.org/10.1101/2020.06.01.20119149
History 
  • July 2, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Francesco Perrone, MD*,1,†,
  2. Maria Carmela Piccirillo, MD*,1,
  3. Paolo Antonio Ascierto, MD2,
  4. Carlo Salvarani, MD3,
  5. Roberto Parrella, MD4,
  6. Anna Maria Marata, MD5,
  7. Patrizia Popoli, MD6,
  8. Laurenzia Ferraris, MD7,
  9. Massimiliano M. Marrocco-Trischitta, MD7,
  10. Diego Ripamonti, MD8,
  11. Francesca Binda, MD8,
  12. Paolo Bonfanti, MD9,
  13. Nicola Squillace, MD9,
  14. Francesco Castelli, MD10,
  15. Maria Lorenza Muiesan, MD10,
  16. Miriam Lichtner, MD11,
  17. Carlo Calzetti, MD12,
  18. Nicola Duccio Salerno, MD13,
  19. Luigi Atripaldi, MD4,
  20. Marco Cascella, MD14,
  21. Massimo Costantini, MD15,
  22. Giovanni Dolci, MD3,
  23. Nicola Cosimo Facciolongo, MD15,
  24. Fiorentino Fraganza, MD4,
  25. Marco Massari, MD15,
  26. Vincenzo Montesarchio, MD4,
  27. Cristina Mussini, MD16,
  28. Emanuele Alberto Negri, MD15,
  29. Gerardo Botti, MD1,
  30. Claudia Cardone, MD1,
  31. Piera Gargiulo, MD1,
  32. Adriano Gravina, MD1,
  33. Clorinda Schettino, MD1,
  34. Laura Arenare, MSc1,
  35. Paolo Chiodini, MSc°,17,
  36. Ciro Gallo, MD°,17 and
  37. on behalf of the TOCIVID-19 investigators (see Appendix for a complete list), Italy
  1. 1Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  2. 2Melanoma. Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  3. 3Università degli Studi di Modena e Reggio Emilia and Azienda USL-IRCCS di Reggio Emilia
  4. 4Cotugno Hospital, AORN Ospedali dei Colli, Napoli
  5. 5Emilia Romagna Health Directorate, Bologna
  6. 6Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma
  7. 7Infectious Diseases Unit, Hospital Health Direction, IRCCS - Policlinico San Donato, Milano
  8. 8Infectious Diseases Unit - ASST Papa Giovanni XXIII, Bergamo
  9. 9Infectious Diseases Unit, ASST Monza and University Milano Bicocca
  10. 10University of Brescia and ASST Spedali Civili, Brescia
  11. 11Sapienza University of Rome, Santa Maria Goretti Hospital, Latina
  12. 12Infectious Diseases and Hepatology Unit AOU Parma
  13. 13UOC Malattie Infettive e Tropicali, AOUI, Verona
  14. 14Anesthesia and Resuscitation Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli
  15. 15Azienda USL-IRCCS di Reggio Emilia
  16. 16Università degli Studi di Modena e Reggio Emilia
  17. 17Department of Mental Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli
  1. ↵†Corresponding author
    Francesco Perrone, Clinical Trial Unit, Istituto Nazionale Tumori di Napoli, f.perrone{at}istitutotumori.na.it, fax +390817702938

  1. ↵* contributed equally

  2. ↵° contributed equally

Back to top
Posted July 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo
medRxiv 2020.06.01.20119149; doi: https://doi.org/10.1101/2020.06.01.20119149
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area